Open-label study with the monoamine stabilizer (-)-OSU6162 in myalgic encephalomyelitis/chronic fatigue syndrome.
Sara HaghighiSara ForsmarkOlof ZachrissonArvid CarlssonMarie K L NilssonMaria L CarlssonRobert C SchuitCarl-Gerhard GottfriesPublished in: Brain and behavior (2021)
(-)-OSU6162 is well tolerated in ME/CFS patients and shows promise as a novel treatment to mitigate fatigue and improve mood and health-related quality of life in ME/CFS. Obviously, the present results need to be confirmed in future placebo-controlled double-blind trials.
Keyphrases
- placebo controlled
- double blind
- open label
- clinical trial
- end stage renal disease
- sleep quality
- phase ii
- phase iii
- study protocol
- newly diagnosed
- chronic kidney disease
- ejection fraction
- prognostic factors
- bipolar disorder
- phase ii study
- squamous cell carcinoma
- randomized controlled trial
- big data
- physical activity
- replacement therapy